Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease primarily affecting the joints. While there are effective treatments available, ongoing research aims to discover new and improved methods to combat RA. Among these novel approaches are JAK inhibitors, BTK inhibitors, vagus nerve stimulation, stem cell therapy, and vaccines.
The American College of Rheumatology (ACR) has released updated guidelines focusing on the medical management of rheumatoid arthritis. These guidelines categorize medications into conventional synthetic Disease-Modifying Anti-Rheumatic Drugs (DMARDs) and offer insights into the latest advancements.
Managing RA involves more than just medication. Activity pacing is crucial. Lightening schedules and seeking help when necessary are recommended. Periodic breaks during the day can conserve energy and protect joints. Hot and cold treatments are also beneficial; heat improves blood flow and eases joint stiffness, while cold helps reduce swelling by constricting blood vessels, thereby easing pain.
However, challenges persist in the fight against RA. Diagnostic delays, limited access to specialists, and the high cost of therapies remain significant barriers for many patients. Even in developed countries, the treat-to-target principle and the goal of achieving disease remission are not always attainable.
Recent research, as published in the New England Journal of Medicine by Josef S. Smolen et al., focuses on Olokizumab, a new contender in RA treatment. This research compares Olokizumab with Placebo or Adalimumab, providing new insights into RA management.
For more detailed information, you can refer to the following sources:
Verywell Health,
American Academy of Family Physicians,
Arthritis Foundation,
PMC, and
Medical Xpress.
